Trial Profile
A phase II trial of PNT 2258 in combination with standard-of-care treatment regimen as second line treatment in 'transplant ineligible' patients with diffuse large B-cell lymphoma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2017
Price :
$35
*
At a glance
- Drugs Rosomidnar (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms Granite
- 09 Jan 2017 According to a Sierra Oncology media release, this trial was originally conducted by ProNAi Therapeutics, Inc. but later on this company's name changed to Sierra Oncology.
- 08 Mar 2016 New trial record